Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cidara Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CDTX
Nasdaq
8731
http://www.cidara.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cidara Therapeutics Inc
Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
- Jan 25th, 2023 4:02 pm
Cidara Therapeutics Nominates First Oncology Clinical Development Candidate from its Cloudbreak® Platform
- Jan 4th, 2023 1:00 pm
Cidara Therapeutics (NASDAQ:CDTX) shareholders are up 19% this past week, but still in the red over the last five years
- Jan 4th, 2023 11:09 am
Cidara Therapeutics Announces Issuance of First U.S. Patent for CD388
- Dec 1st, 2022 1:00 pm
Cidara Therapeutics Announces Two Leading Independent Proxy Advisory Firms Recommend Stockholders Vote “FOR” Proposed Reverse Stock Split
- Nov 29th, 2022 1:00 pm
Cidara Therapeutics and Melinta Therapeutics Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet
- Nov 28th, 2022 1:00 pm
Cidara Therapeutics to Participate in the World Antiviral Congress 2022
- Nov 23rd, 2022 1:00 pm
Cidara Therapeutics Third Quarter 2022 Earnings: Beats Expectations
- Nov 9th, 2022 10:41 am
Cidara Therapeutics to Present at the Stifel Healthcare Conference
- Nov 8th, 2022 1:00 pm
Is Cidara Therapeutics (NASDAQ:CDTX) In A Good Position To Deliver On Growth Plans?
- Nov 7th, 2022 4:58 pm
Cidara Therapeutics (CDTX) Q3 Earnings Miss Estimates
- Nov 3rd, 2022 11:05 pm
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
- Nov 3rd, 2022 9:47 pm
Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2022
- Oct 17th, 2022 12:00 pm
Cidara Therapeutics Receives $11.1 Million Milestone Payment from Mundipharma
- Oct 4th, 2022 12:00 pm
Cidara's Lead Antifungal Candidate Goes Under Priority FDA Review
- Sep 21st, 2022 2:27 pm
Cidara Therapeutics Announces FDA Acceptance for Priority Review of New Drug Application for Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
- Sep 20th, 2022 8:05 pm
Cidara Therapeutics Announces Initiation of Phase 2a Human Viral Challenge Trial to Evaluate CD388 for Universal Prevention of Influenza
- Sep 13th, 2022 12:00 pm
Cidara Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference
- Sep 6th, 2022 12:00 pm
Cidara Therapeutics (CDTX) Reports Q2 Loss, Lags Revenue Estimates
- Aug 9th, 2022 11:25 pm
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
- Aug 9th, 2022 9:16 pm
Scroll